Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
The 4.2% increase in organic revenue was driven by a 4.8% increase in the company's organic Base Business, partially offset by a (0.6%) decrease in COVID-19 testing. Thursday, Laboratory Corp (NYSE:LH) reported third-quarter 2024 adjusted earnings per share of $3.50, up from $3.38 a year ago, beating the consensus of $3.49.
週四，實驗室Corp（NYSE:LH）報告2024年第三季度每股調整收益爲3.50美元，高於去年的3.38美元，超出共識的3.49美元。
Sales increased 7.4% year-over-year to $3.28 billion, almost in line with the consensus of $3.26 billion.
銷售額同比增長7.4%，達到32.8億美元，幾乎與共識的32.6億美元持平。
The increase was due to organic revenue of 4.2%, acquisitions, net of divestitures of 3.1%, and foreign currency translation of 0.1%.
增長歸因於有機收入增長4.2%，收購淨額減除出售的3.1%，外幣翻譯的0.1%。
The 4.2% increase in organic revenue was driven by a 4.8% increase in the company's organic Base Business, partially offset by a (0.6%) decrease in COVID-19 testing.
有機收入增長4.2%，公司有機基礎業務增長4.8%，部分抵消COVID-19檢測下降(0.6%)。
Also Read: Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
還閱讀：診斷巨頭Labcorp、羅氏在全球關注新MPOX變種之際加大檢測能力
Adjusted operating income for the quarter was $441.1 million, or 13.4% of revenue, compared to $423.9 million, or 13.9%, in the third quarter of 2023.
本季度調整後的營業收入爲44110萬美元，佔營業收入的13.4%，而2023年第三季度爲42390萬美元，佔13.9%。
William Blair reported that the operating margin came in about 30 basis points below expectations, primarily due to a lower margin in the diagnostics segment, which stood at 15.2%. This decline was influenced by fewer operational days caused by adverse weather and dilution from Invitae.
William Blair報告稱，營業利潤率低於預期約30個點子，主要是由於診斷業務領域的利潤率較低，爲15.2%。這一下降受到不利天氣導致運營日減少以及Invitae稀釋的影響。
Diagnostics Laboratories revenue for the quarter was $2.55 billion, an increase of 8.9%.
本季度診斷實驗室的營業收入爲25.5億美元，同比增長8.9%。
Biopharma Laboratory Services revenue increased 2.6% to $737.7 million.
生物製藥實驗室服務營業收入增長2.6%，達到73770萬美元。
Guidance: LabCorp expects 2024 adjusted EPS of $14.30-$14.70, compared to prior guidance of $14.30-$14.90 and the consensus of $14.56.
指導：LabCorp預計2024年調整後的每股收益爲14.30美元至14.70美元，相比先前的指導爲14.30美元至14.90美元和市場一致預期的14.56美元。
The analyst notes that adjusted EPS guidance was lowered due to a $0.15 headwind from adverse weather impacts and offset by slightly better underlying trends.
分析師指出，由於不利天氣影響造成的0.15美元的不利影響，調整後的每股收益指南下調，並且受到略微好轉的基礎趨勢的抵消。
The weather impact was slightly greater than expected, but William Blair believes investors will likely overlook this factor, as they did with Quest Diagnostics (NYSE:DGX) earlier in the week.
天氣影響略高於預期，但威廉·布萊爾認爲投資者可能會忽視這一因素，就像他們本週早些時候對Quest Diagnostics（紐交所:DGX）所做的那樣。
The analyst noted that LabCorp could experience a more significant effect from the weather this quarter, given its higher exposure to North Carolina, which was impacted by Hurricane Helene, compared to Quest.
分析師指出，由於其受到颶風海倫影響較大，與Quest（奎斯特診療）相比，LabCorp本季度可能會受到更嚴重的天氣影響。
The company expects 2024 revenue growth of 6.6%-7.3%, compared to the prior guidance range of 6.4%-7.5% and the consensus of 12.96 billion.
公司預計2024年營業收入增長6.6%至7.3%，相比之前的6.4%至7.5%的指導區間和129.6億美元的市場一致預期。
The guidance includes 2024 Diagnostics Laboratories sales growth of 7.2%-7.8% and Biopharma Laboratory Services sales growth of 4.7%-5.6% versus prior guidance of 6.9%-7.9% and 3.7%-5.0%, respectively.
指導包括2024年診斷實驗室銷售增長7.2%至7.8%和生物製藥實驗室服務銷售增長4.7%至5.6%，而不是之前的分別爲6.9%-7.9%和3.7%-5.0%。
Price Action: Laboratory stock is up 6.37% at $233.91 at last check Thursday.
價格表現：上週四最後一次檢查時，實驗室股價上漲6.37%，至233.91美元。
- Harley-Davidson Q3 Earnings: Sales Drop 26%, High Interest Rates Hit Motorcycle Demand And Margins, Lowers 2024 Outlook
- 哈雷戴維森第三季度收益：銷售下降26%，高利率衝擊摩托車需求和利潤，降低了2024年展望
譯文內容由第三人軟體翻譯。
